Free Trial
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$7.87 -0.06 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$7.86 0.00 (-0.06%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Advanced

Key Stats

Today's Range
$7.78
$8.10
50-Day Range
$6.99
$8.30
52-Week Range
$4.33
$8.85
Volume
221,376 shs
Average Volume
207,254 shs
Market Capitalization
$294.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

LFCR MarketRank™: 

Lifecore Biomedical scored higher than 12% of companies evaluated by MarketBeat, and ranked 908th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Lifecore Biomedical is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Lifecore Biomedical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lifecore Biomedical has a P/B Ratio of 196.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lifecore Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    7.73% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently increased by 0.39%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.73% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently increased by 0.39%, indicating that investor sentiment is decreasing.
  • MarketBeat Follows

    1 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LFCR Stock News Headlines

Lifecore Biomedical (LFCR) Initiated with a Hold at KeyBanc
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $7.43 on January 1st, 2025. Since then, LFCR stock has increased by 5.9% and is now trading at $7.87.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.01. The firm had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 846.51% and a negative net margin of 31.70%.
Read the conference call transcript
.

Top institutional shareholders of Lifecore Biomedical include Greenhaven Road Investment Management L.P. (9.88%), Geode Capital Management LLC (2.09%), Grizzlyrock Capital LLC (1.96%) and DCF Advisers LLC (1.24%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs.
View institutional ownership trends
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/07/2025
Today
9/19/2025
Next Earnings (Estimated)
10/03/2025
Fiscal Year End
5/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LFCR
CIK
1005286
Employees
690
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.72 million
Net Margins
-31.70%
Pretax Margin
-30.01%
Return on Equity
-846.51%
Return on Assets
-13.03%

Debt

Debt-to-Equity Ratio
113.76
Current Ratio
2.84
Quick Ratio
1.77

Sales & Book Value

Annual Sales
$128.87 million
Price / Sales
2.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.04 per share
Price / Book
198.25

Miscellaneous

Outstanding Shares
37,410,000
Free Float
25,363,000
Market Cap
$296.66 million
Optionable
Optionable
Beta
0.64
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners